Table 289.1
Abrocitinib Summary of Clinical Safety (Atopic Dermatitis)
Proportion and Incidence Rates of Hypoglycemia (RCP)

	Placebo	Abrocitinib 100mg QD	Abrocitinib 200mg QD	All Abrocitinib
N	1079	819	452	1271
Number of Subjects with Event, n (% [1])	0	0	0	0
Total Drug Exposure (PY)	462.25	218.34	112.42	330.76
Incidence Rates (95% CI) [1]	0.00 (0.00, 0.80)	0.00 (0.00, 1.69)	0.00 (0.00, 3.28)	0.00 (0.00, 1.12)

Includes Studies: B7451006, B7451012, B7451013, B7451029, B7451036
Includes data up to the end of risk period (the smaller of [last dose date, death date] for B7451012/13/36 subjects who enrolled into the LTE study; or the smaller of [last dose date prior to Week 16 dose date/visit date, death date] for B7451029 subjects with available Week 16 dose date/visit date; otherwise, the smaller of [last dose date + 28 days, death date]).
PY (Patient-Year): Total follow up time calculated up to the day of the first event for subjects with events, and up to the end of risk period for subjects without events.
n: Number of subjects with the event. Incidence Rates: Number of subjects with events per 100 patient-years.
Confidence intervals (CI) were calculated for incidence rates based on the assumption that the actual count of cases arises from a Poisson distribution for treatment groups with zero event; otherwise they were based on gamma distribution weighted by study-size.
[1]Study-size adjusted results.
PFIZER CONFIDENTIAL SDTM Creation: 06JUN2025 (10:49) Source Data: adtteae Table Generation: 06JUN2025 (11:25)
Output File: ./ad_2024/scsb7450289a_RCP/adae_imm_hs